New Mexico Cannabis Bill Filed

New Mexico Cannabis Bill Aims to Curtail Unregulated Market

1/17/2024

by

As New Mexico marks the two-year anniversary of legalizing recreational cannabis, state lawmakers are actively revisiting the regulations governing its sale and use. Spearheaded by Senator Katy Duhigg (D-Albuquerque), the legislative body is set to introduce a comprehensive bill that aims to refine and enhance existing cannabis laws, according to a report from local news outlet KRQE.

A key focus of the bill is the burgeoning illegal cannabis market within New Mexico. Senator Duhigg highlighted the challenges posed by illegal cannabis, particularly with products entering from neighboring states. Duhigg estimates that illicit sales currently account for about one third of the New Mexico cannabis market: to combat this, the bill proposes a clear definition of illegal cannabis and escalates penalties for trafficking, with a special emphasis on repeat offenders.

The proposed legislation also seeks to empower the Cannabis Control Division (CCD) by granting it authority to seize illegal cannabis products found during investigations. This move is intended to prevent these products from filtering into the black market, thereby strengthening the legal cannabis industry.

“Now that we’ve had a couple of years to see how recreational cannabis is working in New Mexico, we now know where we need to make adjustments cause we have the benefit of that bug testing.”

– Duhigg, via KRQE

According to the report, another significant change in the bill involves the easing of licensing restrictions. The initial laws prohibited holding both a cannabis and liquor license simultaneously. Duhigg’s bill revises this, allowing individuals to own licenses for both, though not permitting the serving of both substances at the same location. This change is intended to mitigate public safety risks while providing more flexibility for business owners.

The bill also introduces tighter controls on cannabis advertising and packaging. Aimed at reducing appeal to children, the new rules would ban cartoon imagery and require opaque packaging. While the former is a common regulation in state-legal markets, mandatory opaque packaging would be a more extreme restriction that could hinder consumers’ ability to choose which products to buy — likely benefiting brands that focus more on packaging and presentation than product quality.

Despite the limited duration of the 30-day legislative session, Senator Duhigg expressed optimism about the bill’s prospects. She emphasized the importance of these revisions for the numerous New Mexicans who rely on the cannabis industry for their livelihood.

End

Czech Republic’s Adult-Use Cannabis Plan Features Social Clubs, Home Growing

1/16/2024

by

The Czech Republic has published their first draft of laws intended to legalize adult-use cannabis in the country, including plans to decriminalize possession as well as home cultivation, and to create social clubs where people can freely consume. However, according to English-language news outlet Expats.cz, the government’s draft bill does not include a framework for establishing a regulated cannabis market. This omission has reportedly raised eyebrows and led to a flurry of discussions among stakeholders and policymakers, with some advocates suggesting that rules for licensed production and retail could be added in the future.

Since 2010, the Czech Republic has decriminalized cannabis for personal use, and medical cannabis has been legal since 2013. The country’s recent efforts to legalize adult-use cannabis, initiated in late 2022, first included plans to establish a regulated market. However, the latest developments suggest a focus only on possession, home cultivation, and the formation of cannabis social clubs, for the time being.

According to Expats.cz, the “Pirate Party,” a prominent proponent of cannabis legalization in the Czech Republic, considers the current bill a compromise. The party intends to negotiate additional provisions, given that the bill is still under development by a working group since November last year.

The proposed legislation is also part of a broader initiative by the Czech government to address addiction through a scientific and risk-based approach. This approach involves regulating “addictive” substances according to their harm levels and adopting policies for harm reduction in addiction management.

Despite not being finalized, the draft has already attracted criticism for its failure to create a legal market for cannabis. According to the report, Czech cannabis associations have expressed their concerns in a joint press release. They argue that while permitting self-cultivation and cannabis clubs are steps forward, the absence of a regulated market doesn’t fully address the issues arising from the current repressive approach, particularly the profits of illegal producers and dealers.

In a recent interview with Business of Cannabis, Dr. Tomas Ryska of Astrasana Czech, suggested that this move could be a strategic one ahead of the nation’s upcoming elections. By omitting market regulations, the government might pressure the Christian Democrats, a coalition party opposing a commercial market, to change their stance. This plan also aims to create media attention and public discontent, paving the way for introducing a market in a later draft. In a quote from the interview, he states, “Politicians very much listen to what the people who voted for them say because they need their votes, and the elections are coming in 2025.”

This development in the Czech Republic mirrors the challenges faced by other EU countries in establishing a legal adult-use cannabis market. Germany’s revised proposal due to European Commission push-back and the legal hurdles within the EU framework also highlight the complexities involved.

End

Illinois Nets $417M From 2023 Cannabis Tax Revenue

1/16/2024

by

Adult-use cannabis retailers in Illinois sold a record $1.6 billion worth of cannabis products in 2023, which generated $416 million in tax revenue for the state, according to data from the Illinois Department of Financial and Professional Regulation (IDFPR).

“From day one, my administration has put equity first to build the most accessible cannabis industry in the nation. Our work will continue to repair past harm while providing opportunities for communities across the state and creating a more prosperous future.” — Gov. JB Pritzker (D), in a press release

Officials also noted that the sales record coincides with a year-over-year decline in out-of-state sales. In total, about $1.2 billion worth of cannabis products were sold last year to Illinois residents, which is a 14% increase from 2022 and is also higher than the growth of resident sales experienced in 2021, the report said.

“These statistics show encouraging progress that is a testament to the hard work by the Pritzker Administration, lawmakers, and stakeholders in ensuring we create a process that’s accessible to everyone, no matter their gender, race, or where in Illinois they call home,” said IDFPR Secretary Mario Treto, Jr. -“I’m proud of the simplified application process we’ve created to ensure an inclusive cannabis industry and look forward to welcoming even more professionals to the most equitable industry in the country.”

Currently, 177 adult-use cannabis dispensaries, including 67 social equity licensees, have opened for business in Illinois.

A report last year noted that in 2022, Illinois made $36 million in tax revenue off people from Wisconsin — where cannabis remains fully prohibited — who traveled to Illinois to participate in the state’s legal cannabis industry, according to a report.

End

Study Examines Cannabis as Treatment for COVID-19

1/15/2024

by

In a comprehensive review, a group of scientists have brought forth intriguing insights into the potential role of cannabinoids in the battle against COVID-19. The study, titled “Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19,” was authored Cassidy Scott, Stefan Hall, Juan Zhou, and Christian Lehmann. It was published in the Journal of Clinical Medicine.

By analyzing data from numerous past studies, the review explores how components of the cannabis plant could be key in both preventing the onset and mitigating the prolonged effects of COVID-19. The findings suggest that cannabinoids, notably in cannabis extracts, might inhibit the virus’s entry into cells, reduce harmful oxidative stress, and tame the overwhelming immune response often seen in severe cases. This research also highlights the promising role of cannabinoids in addressing the varied and persistent symptoms of Long-COVID.

According to the study, cannabinoids have shown potential in preventing viral entry, mitigating oxidative stress, and alleviating the cytokine storm associated with COVID-19. The study indicates that specific cannabis extracts can downregulate ACE2 protein levels in key tissues, hindering the virus’s entry into human cells. The authors state that this aspect is critical, considering that ACE2 is the primary gateway for the virus.

The review also discusses cannabinoids’ role in addressing oxidative stress, a significant factor in COVID-19’s pathogenesis. By transforming free radicals into less active forms, cannabinoids like CBD could help mitigate the harmful effects of oxidative stress seen in severe COVID-19 cases.

According to the study, cannabinoids may also have a beneficial effect on the cytokine storm, a severe immune response triggered by COVID-19. Cannabinoids have demonstrated effectiveness in reducing inflammatory cytokines, suggesting their potential in managing such immune responses.

Moving to post-acute COVID-19, commonly known as Long-COVID, the study sheds light on the potential of cannabinoids in treating persistent symptoms like depression, anxiety, post-traumatic stress injury, insomnia, pain, and decreased appetite. The endocannabinoid system’s involvement in various neurological processes makes it a target for addressing these neuropsychiatric symptoms.

The study also considered the various methods of consumption and different types of cannabis products used by consumers, and the authors point out that smoke inhalation may have negative effects for patients suffering from respiratory illness that could offset therapeutic benefits.

“Although smoking and vaporizing cannabis are often preferred by patients, as they provide the fastest onset of effects, it is possible that the potential benefits of cannabinoid treatments are outweighed by the negative respiratory health consequences associated with smoking. Studies have suggested that the use of cannabis vaporizers is associated with fewer respiratory symptoms than smoking cannabis, as they do not heat marijuana to the point of combustion.” – Cassidy Scott, et al

The authors underscore the need for further research in this domain. While the initial findings are promising, they caution that these are preliminary and derived from studies not exclusively focused on COVID-19. Therefore, more targeted and extensive research, including clinical trials, is essential to fully comprehend the role and efficacy of cannabinoids in treating early and post-acute SARS-CoV-2 infections. The authors advocate for a deeper dive into the pharmacological aspects and potential therapeutic applications of the endocannabinoid system, urging the scientific community to explore this avenue more rigorously.

End

Feds Release Documents Calling for Moving Cannabis to Schedule III

1/15/2024

by

Officials with the U.S. Department of Health and Human Services (HHS) last week quietly released hundreds of pages of documents detailing the agency’s recommendation that cannabis be moved from Schedule I to Schedule III under the Controlled Substances Act (CSA). The recommendations were released following a FOIA request to Texas-based attorney Matt Zorn of the On Drugs Substack, and Zorn promptly released the documents to the public on Saturday.

While the unredacted documents are not laden with new revelations, the release confirms reports from last year that federal scientists were recommending the shift to Schedule III and reveals the federal agency’s reasoning behind the change.

The 252-page document states that despite being the most commonly used illegal drug, cannabis “does not produce serious outcomes compared to drugs in Schedules I or II” and, in fact, “the vast majority of individuals who use marijuana are doing so in a manner that does not lead to dangerous outcomes to themselves or others.”

Additionally, officials highlighted findings that cannabis could carry significant medicinal benefits — this directly contrasts the plant’s current Schedule I classification, which is reserved for “drugs with no currently accepted medical use and a high potential for abuse.” While the plant was found to carry some risk of physical dependence, HHS noted that the risk of serious outcomes is low. 

HHS Secretary Xavier Becerra told the New York Times that his department has been coordinating with DEA about the potential for rescheduling cannabis and had “communicated to them our position.”

“We put it all out there for them. We continue to offer them any follow up, technical information if they have any questions.” — Becerra, via NY Times

After news of the Schedule III recommendation broke last year, a group of Republican lawmakers urged the DEA Administrator Anne Milgram in a letter to reject the recommendation. DEA would later assert to Congress in a letter revealed early this year that the agency has the “final authority” on any decision regarding the status of cannabis under the Controlled Substances Act.

In terms of the industry, it’s not completely clear what a Schedule III reclassification would bring but cannabis entrepreneurs, scientists, and lobbyists believe it would at the very least relax restrictions on cannabis medicine, research, and banking.

“The importance of a federal agency publicly acknowledging that cannabis is inappropriately classified as a Schedule I substance and has accepted medical use cannot be overstated,” said Saphira Galoob, Executive Director of the National Cannabis Roundtable, in a press release.

End

2024 Cannabis Industry Forecast: Federal, International, and Financial

1/12/2024

by

As the cannabis landscape continues to evolve at a rapid pace, both within the United States and globally, 2024 stands as a pivotal year filled with potential breakthroughs and challenges. In this round-up, Ganjapreneur taps into the insights of industry professionals, offering a diverse array of predictions that shed light on the future of legalized cannabis. Over the coming weeks, we’ll be publishing more round-ups that will dive deeper into the issues facing brands, retailers, and the CBD/hemp industry. (Want to submit your predictions? Click here) Our focus in this installment is on federal reform, international policy, and the financial outlook of the cannabis industry for the coming year.

The journey towards federal legalization in the U.S. has been a complex and often unpredictable path. This year, experts weigh in on the likelihood of significant legislative changes and how these could reshape the industry. Meanwhile, on the international front, changing policies across various countries offer a glimpse into a future where cannabis may play a more prominent role in global trade and healthcare.

Potential Policy Changes & 280E Relief

We are cautiously optimistic that 2024 is going to be a good year for the cannabis industry. If a re/de-scheduling takes place, this could be great news for workers in the cannabis industry, with the elimination of 280e alone, which has squeezed profit margins considerably. A re/de-scheduling would give companies better margins giving them the ability to catch up to other industries by improving their compensation and benefit offerings to more easily attract new talent and retain the great employees they currently have. This should also allow Cannabis employers to gain access to better healthcare provider networks and 401k plans for their employees.

Kara Bradford, CEO Viridian Staffing

It’s an election year so that means campaign promises will be made! In general it will be up to cannabis organizations and supporters to pressure officials to present tangible solutions with timelines and accountability measures. Specifically, the recent very unfortunate death of an Oakland police officer responding to a cannabis business burglary may ramp up SAFE Banking talks and some movement will be made with rescheduling efforts post HHS’s position release.

Frederika Easley, Director of Strategic Initiatives The People’s Ecosystem

One word: unification. As I see it, we still don’t have a unified industry, and we aren’t advocating enough for the needs of small businesses and legacy producers. We need a coalition of people that represents the needs of the already existing community of consumers—and the people who provide cannabis to them—to make sure that federal legalization isn’t just a transfer of power over to mega corporations whose only interest is capital. Together, we are strong. Individually, we are powerless. If we are not operating together as a unit, the people who are aligned against us are going to take control of our industry.

Roger Volodarsky, Founder/CEO Puffco

We foresee several additional states legalizing recreational cannabis in 2024. Federal legalization of medical or recreational cannabis appears to be a long way off, as demonstrated by the inability of the SAFE Banking Act to pass in Congress. 280E is still the number one challenge the industry faces. The high tax burden stifles growth and profitability in the cannabis industry. 280E makes it difficult for cannabis businesses to reinvest in their operations or to compete with prices on the black market.

Cory Parnell, Principal/CEO BGM

Cannabis markets have been long capital constrained with a small investor pool due to being Scheduled 1 at the Federal Level. Before the next presidential election I believe there will be enough political pressure to re-schedule cannabis. This change may take a while to impact areas such as banking, payments, and interstate commerce, but it will have an almost overnight impact on investment capital. Many interested pools of money are waiting in the wings for this federal prohibition to drop. Ideally this will provided the needed injection of capital into struggling cannabis businesses, and at valuations that are competitive.

Kai Kirk – CPO, Blaze Solutions

Finance & Market Landscape

Regardless of the outcome of rescheduling or the potential passage of SAFER Banking, three key issues will remain unaddressed in 2024: 1) Cashless payments will continue to be scrutinized by card companies and will continue to be shut down 2) Access to capital will not improve and social equity license recipients will either struggle to maintain ownership or be unable to operate 3) The ripple effect of the collections crisis will start to be felt across the supply chain– beginning with cultivators– and will lead to an increase in layoffs and receiverships.

Abby Kaufmann, Sales Executive / Board Member CRB Monitor

The conversation about unethical and illegal industry behavior will have much more attention in 2023. The conversation around the larger cannabis industry and more specifically, cannabis social equity failing to, in any tangible way, heal impact caused by the War on Drugs will mature and we will start to see community demand comprehensive solutions to address comprehensive harm. These conversations will move burden away from the businesses and onto the cities and counties that implemented harmful War on Drugs policy.

Anthony Avalos, Co-Founder/President Council of Equity Advocacy San Diego

In 2024, the cannabis industry will implement substantial changes in how debt and overdue payments are managed. We can expect to see:

  • Elevated Focus on Credit and Collection Practices: Companies will intensify their focus on implementing stringent credit evaluations and more effective collection strategies to navigate financial uncertainties.
  • Emergence of Advanced Credit Scoring Tools: Integrating credit reporting systems into specialized associations will revolutionize how businesses assess credit risks, providing more nuanced and accurate evaluations tailored to the dynamics of the industry.
  • Shift Towards Delegating AR Responsibilities: Enterprises will realize the significance of segregating Accounts Receivable functions from sales teams. This will streamline operations, enhance accuracy, and ensure proactive management of credit and collections.
  • Accelerated Submission of Accounts to Collections: To minimize the impact of delayed payments, reduce risk of defaults and foster a more financially stable ecosystem, companies will expedite the submission of overdue accounts to collections within 90 days.

Brett Gelfand, Managing Partner Cannabiz Collects

2024 will be about the survival of the fittest, it’s that simple. Those cutting corners to make a quick buck will not withstand the pressures and pain points the industry is experiencing. Those of us who have taken the more measured, slow and steady approach and built firm foundations, done things the right way, will be rewarded.

Jeremy Zachary, CEO Zen Cannabis

Overall, event marketing spend will further contract and attendance will decline in 2024. Pre-pandemic, there was a surplus of events. Most came back but have reduced their footprint or frequency. And almost all major cannabis events in the western US in 2023 had 30-50% decline, or in one case, was outright cancelled. Trade shows reflect the health of an industry, often a leading indicator. However, licensed operators, the life blood of all aspects of our industry, lack access to capital which is the oxygen to a quintessential growth industry. Gone are the days when companies would exhibit just because they think they need to be there. ROI will be queen (there is a reason why this is the most powerful piece in chess). Trade events are amazing accelerants for professional growth and enterprise success. The ones that offer compelling content both in the conference rooms and exhibit floor, deliver a qualified audience, and listen to the needs of the market will capture the limited event spend. Or as Warren Buffet once said, “Price is what you pay. Value is what you get.”

George Jage, Co-Founder/CEO MJ Unpacked

We’ve seen an IP land grab going on for a few years now, and you should expect the pace of IP litigation to pick up in 2024, particularly for ancillary businesses, such as those involved in AgTech, vaporization, medical devices, and extraction. As competition heats up and new actors enter the market, patents will become a crucial differentiator. Not only do patents protect companies’ innovations, but they also provide long-term value for investors and acquirers. By enforcing their IP portfolios, companies will protect their market positions and demonstrate the strength of their patent portfolios.

Douglas Fischer, General Council Advanced Vapor Devices

In 2024, the cannabis industry is poised for unprecedented growth, but success won’t come to those who go it alone. The mantra for the year is collaboration. Businesses must recognize that operating in separate entities won’t cut it anymore. The key is to be stronger together—combining forces, pooling expertise, and forming strategic partnerships. Investors are increasingly looking for unity in the industry. A combined company of experts not only mitigates risk but also presents a compelling case for sustainable success. It’s a year where teamwork isn’t just an option; it’s the winning strategy.

Jordan Tritt, Founder/CEO The Panther Group

In a momentous year for the U.S. cannabis industry, the number of states with adult-use legalization will hit halfway. Cannabis is legal in 24 states going into 2024, and we’ll break 25 before ’25. This year, we’ll see hopeful operators in states across the country struggle to open their doors, as competition for capital continues to be fierce in ’24. Maryland and New York businesses will finally get the go-ahead but face a fried funding landscape and hurdle after hurdle to become operational. Bootstrapping, ESOPs, and tax loopholes will be all the rage, but only efficient, compliant operations will succeed. Legalization will push forward, as will medical-only programs, and quietly profitable companies will continue to grind, evolve, and expand with the ever-growing market. Many emerging state licensing opportunities in: Delaware, Kentucky, Maryland, Minnesota, New York, Ohio, and Virginia.

Sumer Thomas, VP of Regulatory Operations Canna Advisors

International Cannabis Outlook

Everyone needs to keep their eyes on Europe in 2024. Legalization is expected to become law in Germany in April, and leaders in several other European nations have indicated that once Germany legalizes it, they will proceed with similar policy modernization efforts in their respective countries. Legalization is going to look different in Europe than it does in North America due to continental agreements. However, there are still tremendous opportunities on the horizon, and industry members need to make moves in 2024 to be strategically placed for the coming years. It is very likely that Europe will see more activity than any other region on the planet, including activity in nations that may not be on everyone’s radar right now.

Alex Rogers, Founder/CEO ICBC

European cannabis will continue to implement more progressive cannabis policies and expand national markets. We expect that Germany’s latest cannabis legislation, which includes the reclassification of cannabis as a non-narcotic, expanding the medical market, to be a major catalyst. It’s already happening: Switzerland has begun experimenting with adult-use cannabis programs; the Czech Republic has announced a progressive new cannabis policy; Malta has already legalized cannabis social clubs; and the Netherlands has already kicked off fully legal, comprehensive pilot programs. The year 2024 will likely be deemed a major milestone for cannabis policy in Europe. The end of cannabis prohibition has been initiated, and new market opportunities are on the rise.

Niklas Kouparanis, CEO Bloomwell Group

End

California Cannabis Regulators Announce Product Recalls

1/12/2024

by

On Wednesday, the Department of Cannabis Control in California announced two recalls of cannabis products due to health and safety concerns.

Recall 1: Urban Therapies Distribution’s Gelato Orangeade

The first recall involves a mandatory action against Urban Therapies Distribution, LLC, concerning their Gelato Orangeade hybrid cannabis flower. The recall, issued on January 10, 2024, was triggered by the detection of Aspergillus flavus, a potentially harmful mold, in the product batch numbered GF-271. According to the announcement, the affected product was manufactured on July 12, 2023.

Consumers in possession of this product are advised to check the UID and batch number on their package. If they match the recalled batch, the DCC recommends that you either dispose of the product or return it to the retailer for proper disposal. Ganjapreneur has reached out to Urban Therapies Distribution for comment.

Recall 2: Echsen Industries’ Infused Pre-rolls

The second recall is a voluntary action by Echsen Industries, LLC, concerning their Fog City Farms Shark Bites infused pre-rolls. Initiated on the same day, this recall was due to the presence of the pesticide Spiromesifen, along with Cadusafos and Cyphenothrin, which were also found in the sample results. These substances pose a potential health risk, according to the DCC. The recalled batch, numbered 0628301 and manufactured on June 28, 2023, was sold after July 17, 2023.

Echsen Industries advises customers who have purchased this product to check the UID and batch number. If they match the recalled batch, the product should be disposed of or returned to the retailer. Consumers experiencing any adverse effects should contact a physician.

In response to the recall, Fog City Farms posted on Instagram clarifying that they have never used chemical pesticides. They attributed the contamination to a third-party manufacturing facility, emphasizing that this was an isolated incident affecting only one batch of their Pacific Chem prerolls manufactured in June of the previous year. They assert that the flower provided was clean, supported by their test results.

For more information about these product recalls, please visit the DCC website.

End

Majority of California Labs Barred From Testing Cannabis Flower

1/12/2024

by

Many of California’s cannabis testing labs are currently blocked from testing the potency of flower products — the industry’s most popular consumer option — under new guidelines from the Department of Cannabis Control (DCC) that took effect this year, KTLA reports. Labs that are not compliant with the new guidelines are not allowed to test any cannabis flower products including the buds themselves and non-infused pre-rolls.

At the start of the year, just 12 of the state’s testing labs had met the new requirements but MJBizDaily reported this week that six more labs had become compliant and could resume their testing regiments, bringing the total number of labs equipped for testing flower products to 18.

Previously, 38 labs across California were performing the tests.

“The Department has not been informed of any significant product delays, but there could be a slight delay in some products reaching dispensaries in the near term. To help prevent this from happening, the Department DCC has been prioritizing re-sampling requests from distributors who had samples with labs that cannot currently conduct flower and non-infused pre-roll testing.” — DCC spokesperson David Hafner, via KTLA

Hafner also suggested that more labs’ testing methods would be verified “in the near future.”

DCC regulators introduced the rule change last year and it took effect on October 1, 2023, although compliance with the shift was not required until January 1, 2024. The agency said at the time that the reason for the change was “to ensure all licensed laboratories are using the same standardized cannabinoid test method which will ensure consumers receive accurate and consistent information regarding the cannabinoid content of the cannabis and cannabis product they use or consume.”

Under the new guidelines, regulators hope to deter bad actors from the practice of “lab-shopping,” which occurs when testing labs inflate their potency results so cannabis companies can list the higher potencies on their products, making them more attractive to consumers.

End

Thailand Reverses Course on Cannabis Legalization

1/11/2024

by

Thailand is on the brink of a major shift in its cannabis policy with the introduction of a new law proposed by the Minister of Public Health, Mr. Cholnan Srikaew. According to the Thai Examiner, this law aims to strictly regulate the use of cannabis, focusing solely on medical applications and effectively outlawing its recreational use.

The proposed legislation stipulates that any cannabis product with a THC level above 0.2% is illegal, a stark contrast to the previous more liberal stance that saw the proliferation of cannabis outlets across the nation.

The introduction of this law represents a significant departure from the policies of the former Minister of Public Health, Anutin Charnvirakul, under whom cannabis was legalized and integrated into the Thai Traditional and Alternative Medicine Department. This new direction raises numerous questions, including whether purchasing cannabis will require a medical certificate and how strictly cannabis stores must adhere to the new regulations. The law also specifically bans the sale of cannabis flower, which is the mainstay of both adult-use and medical markets in the US.

This shift in policy also has international implications. Recent seizures of cannabis in Ireland, originating from Thailand, have brought to light the challenges associated with cannabis regulation and enforcement. Thailand’s government must also consider obligations under international drug control treaties, such as the 1971 Convention on Psychotropic Substances, to which Thailand is a signatory.

However, with the emergence of a strong cannabis lobby in Thailand driven by the industry’s profits, there is expected to be stiff resistance to this legislative change. The situation highlights the complexities and divisive nature of cannabis regulation around the world, reflecting broader global discussions and ideology about drug use and plant medicine.

End

Navajo Authorities Charge Two Tribal Members Over Illicit Cannabis Farm

1/11/2024

by

According to a recent report from the Navajo-Hopi Observer, two members of the Navajo Nation, Dineh Benally and Farley BlueEyes, have been formally charged with the illegal cultivation of marijuana. This case, unfolding in Window Rock, Arizona, marks a significant development in an ongoing legal saga that has spanned several years and included accusations of forced labor. On January 4th, tribal prosecutors accused the pair of operating a large marijuana growing operation around Shiprock, New Mexico. Both men are expected to face arraignment later this month, according to the report.

Dineh Benally, a Navajo businessman, had previously faced charges in 2020 for interfering with judicial proceedings. These charges stemmed from a Navajo judge’s order to stop the marijuana farms’ operations in northwestern New Mexico. Benally’s attorney, David Jordan, claimed the interference charges were dismissed in December as the case approached trial. In a statement to the paper, Jordan described the latest charges as harassment and said that Benally insists he was growing hemp, not marijuana.

The controversy first gained public attention in 2020 when local authorities discovered Chinese immigrant workers trimming marijuana in motel rooms near Shiprock. This discovery led to raids by federal, state, and tribal authorities, resulting in the destruction of a quarter-million plants. A group of Chinese immigrant workers has since sued Benally and his associates, alleging they were forced to work long hours trimming cannabis and were lured to New Mexico under false pretenses, according to the report.

Additionally, Benally’s license for another growing operation in central New Mexico was recently revoked by New Mexico regulators due to multiple violations, including the cultivation of far more plants than the license permitted. Benally’s case is particularly noteworthy due to his past as a Navajo Nation presidential candidate who advocated for large-scale hemp farming as an economic opportunity, and who reportedly campaigned under the slogan, “Let’s grow together.”

End

Report: States Have Pardoned 2.3 Million Cannabis Convictions Since 2018

1/10/2024

by

State courts have pardoned or expunged cannabis-related convictions for more than 2.3 million U.S. citizens since 2018, including about 500,000 in just the last year, according to an updated NORML analysis.

The report covers the publicly available data about cannabis pardons and expungements since sweeping efforts to relieve cannabis convictions first started to gain steam. Pardons, which forgive past criminal convictions, are granted by elected officials like a governor or president; expungement, which forgives and seals past convictions from the public, is typically enacted via the legislature or by voter initiative.

Ultimately, expungement policies have accounted for the majority of the relief, including some 800,000 cannabis convictions being sealed by Illinois state officials, more than 300,000 each in New Jersey and Virginia, and about 200,000 each in California and New York, although many other states have also enacted sweeping expungement policies. Elected officials meanwhile have issued cannabis pardons to about 100,000 individuals, the report said.

President Joe Biden (D) in December renewed his call for state governors to pardon state-level cannabis possession charges, a request he first made alongside the October 2022 blanket pardoning of all federal convictions for simple cannabis possession. The president expanded that action last month but he still stopped short of commuting the sentences of any prisoners currently serving time for cannabis-related convictions.

“Hundreds of thousands of Americans unduly carry the burden and stigma of a past conviction for behavior that most Americans, and a growing number of states, no longer consider to be a crime. Our sense of justice and our principles of fairness demand that public officials and the courts move swiftly to right the past wrongs of cannabis prohibition and criminalization.” — NORML’s Deputy Director Paul Armentano, in a press release

Recent polling data suggests that a record 70% of Americans support federal cannabis legalization.

End

Wisconsin Republicans Unveil Highly Restrictive Medical Cannabis Proposal

1/10/2024

by

Republican lawmakers in Wisconsin unveiled a highly restrictive medical cannabis proposal on Monday, drawing an unenthusiastic response from Democratic Gov. Tony Evers, the Associated Press reports.

Under the proposed bill, medical cannabis products would only be legally available to people with chronic illnesses like cancer, and the products would only be available via five state-run retailers that would be designated at a later point by the state Department of Health Services. Additionally, smokable cannabis products would not be available to patients.

A spokesperson for Gov. Evers — who alongside Democratic lawmakers has called for the full legalization of cannabis in Wisconsin — said the governor would review the proposal and that “he looks forward to hearing from Wisconsinites and other stakeholders as the bill moves through the legislative process.”

Wisconsin Republicans currently hold strong majorities in both the House and Senate, and Assembly Speaker Robin Vos has said the proposal is as far as Assembly Republicans are willing to go, the report said.

“We want to make this available to people, but we want to have tight controls on it as well.” — Wisconsin State Rep. Jon Plumer (R), in a statement

Meanwhile, a report published last year found that neighboring Illinois generated about $36.1 million in tax revenue from cannabis sales to Wisconsin residents in 2022. In total, Wisconsinites were estimated to have accounted for nearly 8% of total cannabis sales in Illinois that year, the report said.

End

Florida Bill Would Cap Adult-Use Cannabis at 10% THC

1/09/2024

by

Florida State Representative Ralph Massullo has introduced a bill proposing limitations on the potency of cannabis in the event that adult-use marijuana is legalized in the state later this year. The proposed legislation seeks to set a maximum THC content of 10% for cannabis products intended for smoking and 60% for concentrates. Additionally, marijuana edibles would be subject to a cap of 200 milligrams of THC per package and 10 milligrams per serving.

The text of the bill reads:

Marijuana for personal use may not have a tetrahydrocannabinol potency, by weight or volume, of greater than 10 percent for marijuana in a form for smoking or greater than 60 percent in the final product for all other forms of marijuana, excluding edibles. Edibles for personal use may not contain more than 200 milligrams of tetrahydrocannabinol and a single serving portion of an edible may not exceed 10 milligrams of tetrahydrocannabinol.

Considering that most cannabis for sale in other adult-use markets is over 15% THC and that the rule would apply only to adult-use cannabis, not the current medical cannabis market in Florida, the bill would inherently give medical cannabis brands a significant advantage. However, the possibility of Florida voters encountering an adult-use legalization measure on their November ballots is still in question.

A campaign named Smart & Safe Florida has garnered enough signatures to potentially qualify for the 2024 ballot, but the Florida Supreme Court is currently deliberating on a constitutional challenge against the measure, initiated by Florida Attorney General Ashley Moody.

Most of the campaign’s funding, approximately $39.5 million, reportedly comes from Trulieve, a multi-state, publicly-traded cannabis brand. Moody has accused Trulieve of attempting to monopolize the legal cannabis market in Florida through this initiative.

Despite its introduction, the bill’s chances of success remain uncertain. Previous attempts to limit cannabis flower potency to 10% THC have not passed. For the measure to pass, it would require approval from 60% of voters.

End

Minnesota Regulators and Police Discuss Closing THCA Hemp Loophole

1/09/2024

by

A perceived loophole in Minnesota’s new adult use cannabis law is set to be addressed in a summit later this week, according to a report from news outlet MinnPost. The meeting, convened by the state Office of Cannabis Management and the Department of Health, will bring together law enforcement and local government associations to discuss the unregulated sale of products portrayed as hemp that may contain high THC levels.

The ambiguity arises from the law’s description of regulated products, which includes hemp-derived edibles and beverages but omits raw hemp flower. Consequently, the Office of Medical Cannabis, currently overseeing the regulation until the permanent Office of Cannabis Management is established in 2025, lacks jurisdiction over raw hemp flower. This gap has allowed some hemp retailers and smoke shops to sell raw flower potentially high in THC without regulatory oversight or testing.

State law explicitly states that illegal cannabis sales are a criminal matter, with enforcement responsibility falling to local law enforcement. However, the new Office of Cannabis Management, when operational, will have the authority to take action against illegal sales, including confiscation, testing, and imposing civil fines. In the interim, the state is developing outreach initiatives to assist law enforcement with these issues.

Law enforcement agencies and retailers following the law are seeking clarity and intervention from either state regulators or local police to address retailers who are violating the law. However, they face challenges due to the technical nature of the issue, lack of resources for testing, and legal complexities. The federal regulations on these products are also under debate: despite a memo from the DEA stating that Delta-8 THC and other THC derivatives sourced from hemp are controlled substances, purveyors of these products claim they are operating legally under the rules put in place by the 2018 Farm Bill.

The situation has left many in a confusing in-between period where no clear authority or resources are available to ensure the safety of these products.

A legislative fix to include raw hemp flower under the Office of Medical Cannabis’ regulatory jurisdiction is being considered for the 2024 session. Meanwhile, the Minnesota cannabis community is awaiting guidance and hoping for a resolution.

End

Canada Has Destroyed 3.7 Million Pounds of Cannabis Since 2018

1/08/2024

by

Data from Health Canada shows that Canadian cannabis operators destroyed a record 611.7 million grams (about 1.7 million pounds) of cannabis products and unpackaged cannabis flower in 2022 and during the first half of 2023, MJBizDaily reports.

The number represents about 16% of the industry’s total 2022 production; and, while data from the second half of 2023 is not currently available, the first six months suggested that the industry is inching closer to a supply-demand equilibrium, the report said.

Cannabis industry consultant Farrell Miller said the usual reason for destroying packaged cannabis products is their age.

“There is no demand for old and low-THC products, so manufacturers of finished products are not buying this biomass as inputs. …As consumers become more savvy with packaging dates on dried cannabis products, this trend will only continue.” — Miller, via MJBizDaily

The total amount of cannabis destroyed by Canadian cannabis operators has now exceeded 3.7 million pounds of cannabis and cannabis products.

Canada, which became the first North American country to legalize adult-use cannabis in 2018, has experienced issues of cannabis overproduction since the industry’s launch. Experts say this is at least partly because the country’s publicly held cannabis companies were initially being valued based on the amount of cannabis they could produce, not sell, according to the report.

A poll published last October found that 65% of Canadian cannabis consumers utilize the legal market. Another report from June 2023 found that the Canadian cannabis industry saw its sales grow 157% over the previous two years.

End

After Adult Use Market Launch, Maryland Cannabis Sales Near $700M in 2023

1/08/2024

by

After launching its adult-use market last year, Maryland cannabis retailers and dispensaries together have sold nearly $700M in products, according to a report from CBS Baltimore. According to the report, medical cannabis, which was already a thriving sector, saw an increase of over $200 million in just about five months. On the other hand, adult use sales rose to $270 million since stores opened.

In a statement to CBS, President of SunMed Growers Jake Van Wingerden highlighted the dramatic impact that adult use legalization has had on their business.

“Once legalization happened we were able to stabilize and a lot of our projections came true. […] We recently at SunMed gave the entire staff a 5-dollar-an-hour raise across the board. So, we were very excited to be able to reinvest back into our team and our people.”- Van Wingerden, to CBS

A portion of Maryland’s cannabis revenue is being redirected to benefit communities statewide. Consumers are charged a 9% tax at the point of sale, which, from July to September alone, amounted to over $12 million in taxes for adult-use cannabis. This is allocated across Maryland’s counties and infused into various funds dedicated to health, business, social equity, and the state’s general fund.

Like many other states, Maryland is also taking proactive steps to expand and diversify the industry. Starting this year, the state is issuing 75 new dispensary licenses via a lottery system, particularly targeting jurisdictions disproportionately impacted by the war on drugs.

This initiative aims to promote market share and ensure a more inclusive and equitable industry. Baltimore City received the lion’s share in the first round with 11 licenses, followed closely by Montgomery and Prince George’s counties, each receiving 9.

If cannabis sales in Maryland continue on their current trajectory, retailers in the state should be on track to generate well over $1 billion in revenue collectively in 2024.

End

Scientific Study Finds Cannabis Makes Exercise More Enjoyable

1/05/2024

by

The long-standing stereotype that cannabis use leads to inactivity is being challenged by new research suggesting that cannabis might actually make working out more enjoyable. The study, titled “Acute Effects of Ad Libitum Use of Commercially Available Cannabis Products on the Subjective Experience of Aerobic Exercise: A Crossover Study” conducted by researchers Laurel P. Gibson, Gregory R. Giordano, L. Cinnamon Bidwell, Kent E. Hutchison, and Angela D. Bryan, sheds light on the relationship between cannabis use and exercise, potentially changing the narrative surrounding cannabis consumption.

The study aimed to examine the acute effects of legal-market cannabis on regular users’ subjective responses to exercise in a controlled laboratory environment. The research team compared participants’ experiences of exercise without cannabis to their experiences after using commercially available cannabis flower products, either THC-dominant or CBD-dominant.

The study recruited 42 volunteers from the Boulder, Colorado area who regularly incorporate cannabis into their running routine. Initially, the researchers established a baseline by measuring fitness levels and gathering survey data. Participants were then instructed to obtain either a CBD-dominant or THC-dominant cannabis strain from a dispensary. During a follow-up visit, volunteers ran on a treadmill for 30 minutes at a moderate pace. Throughout this exercise, they were asked to report on various factors including motivation, enjoyment, perceived exertion, time perception, and pain levels to assess the subjective impact of cannabis on their workout experience.

The results were intriguing. Participants, all regular cannabis users, reported a more positive affect, increased enjoyment, and heightened “runner’s high” symptoms during their cannabis-influenced exercise sessions compared to non-cannabis sessions. However, they also experienced more exertion. Notably, pain levels remained low and consistent across both scenarios. The study observed that effects varied depending on the cannabinoid content, with people who consumed CBD showing a larger difference in enjoyment and a smaller difference in exertion compared to THC consumers.

While the study did not find cannabis to be performance-enhancing in a way that might give competitive athletes an unfair advantage, it highlights its potential to positively influence the subjective exercise experience for regular users. This insight is particularly relevant as many sports leagues, recognizing the medical value of cannabis and its role in recovery, have relaxed their policies on cannabis and CBD. Notably, the UFC recently removed cannabis from their banned substances list, with numerous other professional sports leagues relaxing policies in varying degrees.

The research team’s findings suggest that cannabis, when used in conjunction with exercise by regular users, may lead to an increase in both positive and negative aspects of the subjective exercise experience. However, they caution that more research is needed to establish these findings, calling for diverse samples, exercise modalities, and methodologies, including placebo-controlled trials.

This study stands as the first to investigate the acute effects of commercially available cannabis on subjective responses to exercise in a laboratory environment. It opens the door to a new understanding of how cannabis can interact with physical activity, challenging the stereotypical classification of cannabis consumers as sedentary. As the legal landscape and public perception of cannabis continue to evolve, this research provides a timely insight into how it might be used to enhance rather than hinder an active lifestyle.

End

Cannabis Payment Processor Shuts Down, Files $500M Lawsuit

1/05/2024

by

Cannabis brands have been facing a significant challenge in accessing financial services since states began to legalize the plant. This struggle has been highlighted by a recent lawsuit filed by FP Omni Technologies, a cannabis-friendly payment processor, against TSYS Acquiring Solutions, LLC (“TSYS”), a subsidiary of Global Payments, Inc. The lawsuit, filed in the Superior Court of Gwinnett County, Georgia, details FP Omni’s claims against TSYS, alleging false representation and a breach of contract.

In a press release published on December 28th, FP Omni Technologies, based in Peachtree City, Georgia, announced its decision to wind down operations. Since 2020, the company has provided hundreds of dispensaries and their customers with a compliant way to process legal cannabis transactions.

According to the announcement, the issues leading to the shutdown stem from FP Omni’s inability to continue payment processing services promised by TSYS. The two parties had reportedly entered into a long-term agreement in 2019, which FP Omni alleges TSYS has not honored. Specifically, FP Omni claims TSYS misrepresented its ownership and control over the payment gateway through which FP Omni’s transactions were processed and failed to provide the agreed-upon payment processing services without the consent of any other entity.

FP Omni believes that, as a result of TSYS’ continuing actions and inactions, the company could no longer service its customers properly. 

– Excerpt from the press release

The lawsuit gained momentum on September 29, 2023, when the trial court denied TSYS’ request for dismissal. The court ruled that FP Omni could proceed with its claims for breach of contract, fraud, negligent misrepresentation, and breach of implied duties of good faith and fair dealing. FP Omni seeks compensatory and punitive damages, and the latest valuation of the company exceeded $500 million. A copy of the lawsuit and court order can be viewed on the FP Omni website.

One key aspect of FP Omni’s operations was its use of pin debit transactions, a method singled out by major credit card processors earlier in the year. This method was considered one of the few available to cannabis businesses due to the federal illegality of cannabis, which restricts traditional banking and credit card processing options. The lawsuit and FP Omni’s subsequent shutdown highlight the ongoing difficulties cannabis businesses face in accessing essential financial services.

FP Omni says they are determined to continue their litigation against TSYS vigorously. The company aims not only to recover the full value of its lost business but also to expose the actions of TSYS and others involved in stifling a legal, competitive cannabis payment processing industry.

End

DEA Letter to Congress Asserts “Final Authority” on Cannabis Scheduling

1/04/2024

by

In a recent letter to congress that was published by Punchbowl News, a DEA representative asserted that the Drug Enforcement Administration has “final authority” on any decision regarding the status of cannabis under the Controlled Substances Act. Amid numerous active efforts to change how the federal government treats cannabis that have been playing out in congress, courts, and the executive branch, this assertion by the DEA highlights the complexity of the situation.

The DEA is currently reviewing the federal classification of marijuana as a Schedule 1 drug, following a recommendation from the Department of Health and Human Services (HHS) to reclassify cannabis to a less restrictive Schedule III, indicating a shift in perspective on its medical value and potential for abuse. Meanwhile, public support of cannabis legalization is at an all-time-high: a recent Gallup poll revealed that seven in ten Americans support a change in policy.

While the HHS has made its stance clear, the DEA holds the final authority to reschedule or deschedule drugs under the Controlled Substances Act. Despite the ongoing review initiated under President Biden’s directive, the DEA has not provided a timeline or clear indication of its position, maintaining a secretive and procedural stance.

This lack of transparency and the DEA’s power to make a final decision have caused frustration among lawmakers, advocates, and the public. Critics argue that the DEA should align with the evolving public opinion and Congressional calls for legalization. In response, Rep. Earl Blumenauer, co-chair of the Congressional Cannabis Caucus, and other lawmakers have urged the DEA to recognize the merits of legalization and consider a more progressive approach during their review.

The secretive nature of the HHS’s rationale for recommending the rescheduling of cannabis, with only heavily redacted documents available to the public, further complicates the issue. Although the Congressional Research Service suggests that the DEA might follow the HHS’s recommendation based on historical precedent, the agency’s current opaque approach leaves the outcome uncertain.

As the debate continues, stakeholders eagerly await the DEA’s decision, which will have significant implications for federal cannabis policy and broader efforts towards reform.

End

Oklahoma Introduces ‘Secret Shoppers’ to Help Regulate Medical Cannabis Industry

1/04/2024

by

Under an Oklahoma state law taking effect this week, the Oklahoma Medical Marijuana Authority (OMMA) can now utilize “secret shoppers” in its effort to regulate the state’s medical cannabis industry, FOX25 reports. Specifically, the new law requires regulators to send at least 50 secret shoppers per year to licensed retailers to anonymously purchase medical cannabis products, and then have the products tested by a lab.

Rep. Josh West, who co-sponsored the bill, said the new law prioritizes the safety of Oklahomans by keeping potential bad actors in check. “Constituents, people in the industry, people outside of the industry, the average public, they wanted some checks and balances in place,” he said in the report.

“Consumer safety is the biggest part of it. And we want to ensure that we are keeping the bad actors out. And so it’s no different than what ABLE does when ABLE goes into a liquor store and ensures that they’re following the law.” — Rep. West, via FOX25

The bill (HB3971) was passed and signed into law in 2022 but didn’t take effect until the start of 2023.

The new law represents Oklahoma‘s latest strategy for cracking down on illegal cannabis operations in the state.

Cannabis regulators said in November they were seeking to revoke 165 medical cannabis cultivation licenses over the companies’ failure to post signage on their properties as required by state law, while the Oklahoma Bureau of Narcotics said in August that over the previous two years, officials shut down more than 800 unlawful cannabis farms.

State officials said last month that throughout their efforts to rein in the industry, the number of licensed medical cannabis cultivators in the state has dropped from about 9,400 in 2021 to about 3,200 at the end of 2023.

End

CBD.market Responds to Growing Evidence That CBD Enhances Sleep

1/03/2024

by

Recent research from medical experts at the University of Northern Colorado, the University of Utah, and the University of Illinois at Chicago indicated that taking 50 mg of CBD may significantly impact sleep quality while enhancing Natural Killer (NK) immune cell function. The study explored various claims regarding CBD and sleep and the human immune system’s role in regulating sleep. Online retailer CBD.market has responded to the growing interest in CBD products to promote natural sleep methods.

The Rising Trend in Using CBD for Sleep Management

Many people are desperate for high-quality sleep at night because of their stressful daytime environments. At the same time, they are reluctant to take prescription sleep aids because of potential side effects and the possibility of dependency. CBD offers a natural way to aid circadian sleep rhythms.

The study followed 28 participants with an average age of 25.9 years for eight weeks who took 50 mg of CBD nightly and were not currently taking sleep medications. Participants received either CBD or a placebo. After completing the eight-week course, the researchers found no significant changes in weight, BMI or body fat percentages among those taking CBD. However, the CBD group experienced significant improvements in sleep quality. This study confirms anecdotal evidence that CBD users experience better sleep.

Researchers believe CBD affects sleep by working on the endocannabinoid system (ECS) in the hypothalamus, impacting sleep regulation and body temperature. CBD can suppress stress hormone overactivation and equalize the sleep and wake rhythm.

CBD.market Delivers High-Quality Products for Better Sleep

CBD.market has recognized the sleep-related CBD demand by responding with increased products geared toward those who want better sleep quality. Overall, gummies are the preferred method of using CBD because they deliver a premeasured dose and are discreet.

“The most popular sleep support products in our store are CBD gummies, CBN gummies, ones with melatonin and other sleep aid additives,” said Michael Levin, CBD.market Head of Analytics. “Following these, tinctures and capsules are also in high demand.”

Consumers seeking high-quality CBD products for sleep and other uses will find many items available at CBD.market. Among the trusted CBD brands CBD.market sells are Wyld CBD, Lazarus Naturals, Joy Organics, NuLeaf Naturals and several others, all thoroughly tested by third parties prior to sale. The company offers a 30-day money-back guarantee to ensure customer satisfaction.

About CBD.market
CBD.market is a top online retailer focusing on elevating and educating consumers on how to use CBD for better wellness. The company provides access to premium CBD products from top-quality manufacturers, with efficacy tested by independent labs. Operating out of its headquarters in San Diego, the company remains on the cutting edge of CBD research to offer the best organic edibles, capsules, tinctures and more to prevent and treat disease and illness in a holistic manner. As the industry leader in high-quality CBD products, CBD.market maintains transparent shipping policies that have helped customers throughout the United States enjoy delivery of these products at reasonable prices.

To contact CBD.market please visit cbd.market or call 422-777-0177, or email info@cbd.market.

End

UFC Removes Cannabis From Banned Substances List

1/03/2024

by

The Ultimate Fighting Championship (UFC) has taken a significant step in sports health and safety by formally removing marijuana from its list of banned substances for athletes, setting a progressive example in the realm of professional sports.

The UFC’s decision to exclude cannabis from its prohibited substances is an extension of its earlier reform in 2021, which protected fighters from being penalized for testing positive for THC. The revised anti-doping policy aims to align with the World Anti-Doping Agency’s (WADA) list, yet it notably deviates by excluding marijuana, reflecting a more nuanced approach to substance regulation in sports.

In a press statement, UFC Chief Business Officer Hunter Campbell highlighted the organization’s ambition to lead with the “most effective and progressive anti-doping program in all of professional sports.” The policy, which came into effect on December 31, is part of UFC’s broader effort to ensure a fair and safe competitive environment. This initiative also includes a new partnership with Drug Free Sport International for sample collection and shipping, further solidifying UFC’s commitment to athlete health and performance integrity.

Jeff Novitzky, UFC Senior Vice President of Athlete Health and Performance, emphasized that the updated anti-doping program is the culmination of extensive input and trial, signifying an ongoing commitment to evolve based on scientific evidence and athlete welfare. The move is seen as a significant stride in acknowledging the changing societal and scientific perspectives on marijuana use and its implications for athletes.

The UFC’s policy shift mirrors a broader trend in sports organizations reevaluating their stance on marijuana amidst a growing legalization movement. Several entities have recently adjusted their drug policies to be more accommodating of cannabis use in the past few years, including the NCAA, NBA, and NFL, among others.

State sports regulators and other organizations like the New York Media Softball League have also adapted their approaches, reflecting a shift in recognizing the potential therapeutic benefits and reduced stigma surrounding marijuana. These changes in the sports world align with a broader societal shift toward more progressive views on cannabis, particularly given its legal status in various jurisdictions.

However, despite these evolving perspectives, the World Anti-Doping Agency continues to maintain a ban on cannabis, citing concerns about the “spirit of sport” and athlete role modeling. This stance has drawn criticism, particularly in the wake of high-profile cases like U.S. runner Sha’Carri Richardson’s Olympic suspension for a positive THC test. The case spurred a widespread call for policy reform, including from the U.S. Anti-Doping Agency, the White House, and congressional lawmakers, highlighting a growing consensus that international rules on marijuana need to be reconsidered to reflect contemporary understanding and attitudes toward the substance.

End

New Mexico Regulators Revoke Two Cannabis Cultivator Licenses

1/03/2024

by

The Cannabis Control Division (CCD) of the New Mexico Regulation and Licensing Department on Tuesday revoked the licenses of two adult-use cannabis cultivators, the agency said in a press release.

The operators in question — Bliss Farm and Native American Agricultural Development Company (NAADC), both located in Torrance County — were said to have exceeded the legal plant count limits and failed to properly utilize the state’s mandatory track-and-trace system. Regulators noted at both locations signs of a recent harvest without any record of the plants or where they might have gone. Additionally, the companies were said to have fostered unsafe working conditions, among other violations.

Under the order, the companies must immediately cease their commercial operations and, in addition to losing their licenses, they have been ordered to pay $1 million in fines. Under state law, such cannabis industry fines go into the state’s school fund.

Clay Bailey, the Acting Superintendent of the New Mexico Regulation and Licensing Department, said in the release, “The illicit activity conducted at both of these farms undermines the good work that many cannabis businesses are doing across the state.”

“Compliance within the industry is the CCD’s main priority and our office is committed to ensuring New Mexicans have access to safe cannabis products. The team worked diligently on both of these cases to determine the appropriate action for violations at a scale we hadn’t seen before. The outcomes were justified under the law based on the egregious conduct of these individuals and I hope this serves as a reminder to those who might be violating the laws and rules the state has put forth.” — Todd Stevens, Cannabis Control Division Director, in a statement

After the order, New Mexico regulators have revoked six cannabis industry licenses since the market’s January 2022 launch.

End

Police Officer Killed While Responding to Burglary at Cannabis Business

1/02/2024

by

Tragedy struck the Oakland Police Department early Friday morning as Officer Tuan Le, 36, lost his life in the line of duty while responding to reports of a burglary at a cannabis business, as reported by CBS. This marked the second burglary incident at the same location within just four hours.

Officer Le, originally from Vietnam, moved to Oakland and became a naturalized citizen on September 11, 2001. He graduated from the 183rd police academy in 2020 and had been serving as the community resource officer in West Oakland for the past two years.

In a heartfelt statement, the Oakland Police Department expressed their grief, stating, “Officer Le was a devoted husband to his wife. His passing leaves a void in the law enforcement community, the city of Oakland, and in the hearts of those who knew him. He will be remembered for his kindness, his smile, and the positive change he brought to the lives of those around him. He is a true hero who dedicated his life to making our community safer.”

The shooting has once again brought to the forefront a critical issue concerning the federal status of cannabis in the United States. While many states have legalized or decriminalized cannabis for medical and recreational use, it remains classified as a federally illegal substance. This conflicting legal landscape forces cannabis dispensaries to operate predominantly as cash-based businesses, making them vulnerable targets for robberies.

Without access to traditional banking services, such as credit card processing and business loans, dispensaries are left with little choice but to deal primarily in cash. This cash-heavy environment not only poses significant security risks but also complicates financial management, tax reporting, and regulatory compliance.

Dispensary operators and advocates have been calling for federal reform for years, emphasizing the urgent need to address the discrepancies between state and federal cannabis laws. The ongoing federal prohibition not only endangers the safety of those involved in the cannabis industry but also puts law enforcement officers like Officer Tuan Le in harm’s way when responding to incidents at these businesses.

Reform efforts have gained momentum in recent years, with calls for comprehensive legislation that would provide a safe and legitimate banking framework for the cannabis industry. The SAFE Banking Act, for instance, aims to allow cannabis-related businesses access to the traditional banking system, reducing their reliance on cash transactions and minimizing the associated risks.

End